Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design.Gorman, J., Soto, C., Yang, M.M., Davenport, T.M., Guttman, M., Bailer, R.T., Chambers, M., Chuang, G.Y., DeKosky, B.J., Doria-Rose, N.A., Druz, A., Ernandes, M.J., Georgiev, I.S., Jarosinski, M.C., Joyce, M.G., Lemmin, T.M., Leung, S., Louder, M.K., McDaniel, J.R., Narpala, S., Pancera, M., Stuckey, J., Wu, X., Yang, Y., Zhang, B., Zhou, T., Program, N.C., Mullikin, J.C., Baxa, U., Georgiou, G., McDermott, A.B., Bonsignori, M., Haynes, B.F., Moore, P.L., Morris, L., Lee, K.K., Shapiro, L., Mascola, J.R., Kwong, P.D.
(2016) Nat.Struct.Mol.Biol. 23: 81-90
- PubMed: 26689967
- DOI: 10.1038/nsmb.3144
- Primary Citation of Related Structures:
- PubMed Abstract:
Broadly neutralizing antibodies (bNAbs) against HIV-1 Env V1V2 arise in multiple donors. However, atomic-level interactions had previously been determined only with antibodies from a single donor, thus making commonalities in recognition uncertain. H ...
Broadly neutralizing antibodies (bNAbs) against HIV-1 Env V1V2 arise in multiple donors. However, atomic-level interactions had previously been determined only with antibodies from a single donor, thus making commonalities in recognition uncertain. Here we report the cocrystal structure of V1V2 with antibody CH03 from a second donor and model Env interactions of antibody CAP256-VRC26 from a third donor. These V1V2-directed bNAbs used strand-strand interactions between a protruding antibody loop and a V1V2 strand but differed in their N-glycan recognition. Ontogeny analysis indicated that protruding loops develop early, and glycan interactions mature over time. Altogether, the multidonor information suggested that V1V2-directed bNAbs form an 'extended class', for which we engineered ontogeny-specific antigens: Env trimers with chimeric V1V2s that interacted with inferred ancestor and intermediate antibodies. The ontogeny-based design of vaccine antigens described here may provide a general means for eliciting antibodies of a desired class.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland, USA.